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Abstract
Gliomas are highly infiltrative tumors incurable with surgery. Although surgery removes the
bulk tumor, tumor cells in the periphery are left behind resulting in tumor relapses. The aim
of the present study was to characterize the phenotype of tumor cells in the periphery focus-
ing on tumor stemness, proliferation and chemo-resistance. This was investigated in situ in
patient glioma tissue as well as in orthotopic glioblastoma xenografts. We identified 26 glio-
mas having the R132 mutation in Isocitrate DeHydrogenase 1 (mIDH1). A double immuno-
fluorescence approach identifying mIDH1 positive tumor cells and a panel of markers was
used. The panel comprised of six stem cell-related markers (CD133, Musashi-1, Bmi-1,
Sox-2, Nestin and Glut-3), a proliferation marker (Ki-67) as well as a chemo-resistance
marker (MGMT). Computer-based automated classifiers were designed to measure the
mIDH1 positive nucleus area-fraction of the chosen markers. Moreover, orthotopic glioblas-
toma xenografts from five different patient-derived spheroid cultures were obtained and the
tumor cells identified by human specific immunohistochemical markers. The results showed
that tumor cells in the periphery of patient gliomas expressed stem cell markers, however
for most markers at a significantly lower level than in the tumor core. The Ki-67 level was
slightly reduced in the periphery, whereas the MGMT level was similar. In orthotopic glio-
blastoma xenografts all markers showed similar levels in the core and periphery. In conclu-
sion tumor cells in the periphery of patient gliomas have a stem cell phenotype, although it
is less pronounced than in the tumor core. Novel therapies aiming at preventing recurrence
should therefore take tumor stemness into account. Migrating cells in orthotopic glioblas-
toma xenografts preserve expression and stem cell markers. The orthotopic model there-
fore has a promising translational potential.
Introduction
Treatment of gliomas is a major challenge. Despite treatment consisting of surgery, chemother-
apy and radiation the mean survival of patients with the most common and malignant primary
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brain tumor, the WHO grade IV Glioblastoma multiforme (GBM), is approximately 14.6
months [1]. A major challenge in treatment of gliomas is the high migratory potential of gli-
oma cells [2]. Migrating glioma cells are not eligible to surgery and therefore eradication by
radiation and chemotherapy is standard strategy.
The high resistance of gliomas against conventional radiation and chemotherapy has been
suggested to be due to the existence of immature cancer stem cells (CSC), which are tumor
cells with a stem cell-like phenotype sustaining glioma growth through asymmetric cell divi-
sion [3, 4]. These cells have been suggested to be resistant towards conventional treatment due
to enhanced DNA repair and enhanced expression of ATP-binding cassette drug transporters
[5]. The presence of CSCs in the periphery of gliomas has not previously been thoroughly
investigated. We therefore hypothesized that migrating glioma cells display a stem cell pheno-
type and express stem cell markers. Since proliferation and chemo-resistance are important
determinants for the effect of radiation and chemotherapy, the markers Ki-67 and MGMT
were included. The aim of this study was to characterize the expression of stem cell markers as
well as markers of proliferation and chemo-resistance in migrating glioma cells by using a dou-
ble immunofluorescence approach on patient glioma tissue and GBM xenografts.
In patient tumor tissue a mutated form of Isocitrate dehydrogenase 1 (mIDH1) [6] was
used as a tumor cell specific marker. The somatic point mutation that affects codon 132 is the
most frequent IDH1 mutation and a specific well described antibody recognizing mIDH1 R132
has recently been developed [7, 8]. This mutation is primarily associated with grade II and III
gliomas but is also found in secondary GBMs [9].
In glioma research the most preferred in vivo model is the orthotopic xenograft model. Here
GBM cells are implanted into the brain of immunosuppressed animals. The model is well
established in our laboratory and has been described by several groups [10, 11]. Using this
model together with a double immunofluorescence approach and human specific markers to
identify the tumor cells, the marker expression in migrating glioma cells was characterized. For
this characterization a panel of markers similar to that used for patient gliomas was used.
We have previously used fluorescence for quantification of biomarkers in gliomas [12]. In
this study we combined the tumor cell specific markers in a double immunofluorescence proto-
col with the following panel of stem cell markers: CD133 [4, 13–18], Nestin [18–24], Musashi-
1 [18, 25–28], Sox-2 [18, 29–32] and Bmi-1 [18, 29, 32, 33], to characterize the phenotype of
migrating glioma cells. We also investigated the glucose transporter type III (Glut-3) in the
core and periphery since it has been reported to be associated with stemness [34]. Furthermore,
we investigated the expression of the DNA repair enzyme O6-methylguanine-DNA methyl-
transferase (MGMT) in the core of the tumor and compared it to the periphery, since MGMT
is a strong prognostic and predictive marker for the effect of temozolomide in the upfront
GBM treatment [35]. The proliferation of migrating tumor cells has previously been investi-
gated by Sabit et al. [36] who investigated 11 patients. We wanted to futher explore this in our
cohort consisting of 26 patients as well as by using the orthotopic GBM xenograft model.
Material and Methods
Patient selection and pathology
Adult residents in the Region of Southern Denmark diagnosed with primary brain cancer
between 1st of January 2005 and 31st of December 2009 were identified in the Danish Cancer
Register (DCR). Patients with the histopathological codes for gliomas (M 94003, M 94013, M
94403, M 94503, M 94513, M 93823, and M 93853) were considered for inclusion in the pres-
ent study, giving a total of 277 patients. The mIDH1 status was identified by immunohisto-
chemical staining; 47 patients were mIDH1 positive. Twenty six patients were identified with
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both a tumor core and a periphery zone present in the same tumor section. The different
mIDH1 positive gliomas are listed according to the WHO classification in Table 1. The histo-
pathological evaluation was carried out at the Department of Pathology at Odense University
Hospital. All tissue samples were evaluated by two pathologists and classified according to
WHO guidelines 2007 [37].
Xenograft model
For establishing the orthotopic xenograft model we used 5 different GBM spheroid cultures,
established in our laboratory from patient-derived GBM tumor tissue, collected at the Depart-
ment of Neurosurgery, Odense University Hospital. Tumor cells were grown and stem cell phe-
notypes validated as previously described in our laboratory [38]. The five GBM spheroid
cultures were named: T78, T86, T87, T111 and T113.
Female Balb c nu/nu mice 7–8 weeks of age were anesthetized subcutaneously with injection
of a mixture of Hypnorm and Dormicum (0,1ml/10g). The mice were placed in a stereotactic
frame (Model 900, David Kopf Instrument). A midline incision was made exposing bregma
and a burr hole was made 1 mm anterior and 2 mm lateral to bregma. A syringe (2 μl Hamilton
syringe) with a blunt needle containing 150.000 cells/μl was inserted 3 mm into the brain and
2 μl were injected slowly into the brain over several minutes. The needle was slowly removed to
prevent a vacuum causing the tumor cells to escape. The skin was sutured with resorbable
sutures. If the mice showed any signs of neurological deficit or weight loss more than 20%,
the mice were euthanized in a carbon dioxide chamber. The brains were immediately removed
and fixated in 4% formalin for 48 hours. Before paraffin embedding the brains were manually
divided by 1mm coronal sections. Histological sections were afterwards cut and immunohisto-
chemically stained with Vimentin, a human specific antibody. In mice implanted with the
GBM spheroid culture T86 CD56, another human specific antibody, was used for identification
of the tumor cells. The GBM spheroid cultures T86 and T113 were found to have unmethylated
MGMT promoter, whereas the remaining GBM spheroid cultures were methylated in the pro-
moter region. We therefore did not investigate the MGMT in the in vivomodel. We defined
the core in our in vivo model as striatum and the periphery as corpus callosum in the contra
lateral side.
Immunohistochemical staining
Histological sections of three μmwere cut on a microtome and placed on glass slides. Tissue
was deparaffinized, and antigen retrieval was carried out in a microwave oven using the Tris
Table 1. Summary of patients.
Histopathological diagnosis Number of mIDH1 patients Age (years) WHO grade
Median Range
diffuse astrocytoma 6 (23.1%) 41 30–62 II
oligodendroglioma 7 (26.9%) 48.9 31–81 II
oligoastrocytoma 5 (19.2%) 46.8 26–74 II
anaplastic astrocytoma 2 (7.7%) 46 34–58 III
anaplastic oligodendroglioma 1 (3.8%) 38 38 III
anaplastic oligoastrocytoma 2 (7.7%) 41 36–46 III
glioblastoma 3 (11.5 %) 60.3 43–75 IV
Total 26 46.7 26–81
doi:10.1371/journal.pone.0155106.t001
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EGTA buffer. Slides were stained on the AutostainerPlus platform (DAKO, Glostrup, Den-
mark). For mIDH1 staining slides were incubated with antibody (mIDH1 R132H, Clone H09,
Dianova, 1:100) and the detection system ultraViewTM Universal DAB Detection Kit (Ven-
tana Medical Systems) was subsequently used. For each patient, tumor slide was stained by a
double immuno-fluorescence approach combining mIDH1 and 6 different stem cell-related
markers: CD133 (clone: W6B3C1, Miltenyi Biotec), Musashi-1 (clone:14H1, MBL Interna-
tional), Bmi-1 (clone: F6, Upstate Cell Signaling Solution), Sox-2 (clone: 245610, R&D Systems
Inc.), Nestin (clone: 196908, R&D Systems Inc.), Glut-3 (clone: HPA006539, Atlas Antibodies),
MGMT (clone: MT23.2, Invitrogen) and the proliferation marker Ki-67 (clone: MIB1, Beck-
man Coulter). The CSA II Biotin-free Tyramide signal Amplification System kit (DAKO) was
used for detection of mIDH1 (1+1600). Detection of the second antibody was performed using
a Tyramide Signal Amplification (TSA) Plus System with Cyanin 5 (Cy5); CD133 (1+40),
Musashi (1+200), Bmi-1 (1+200), Sox-2 (1+400), Nestin (1+200), GLUT-3 (1+100), MGMT
(1+100) and Ki67 (1+800). The nuclei were counterstained with 4´,6 diamidino-2-phemylin-
dole (Dapi) (VWR Internation ApS).
For each xenograft slide a double immuno-fluorescence staining with Vimentin and the same
six stem cell markers and Ki-67 was made. For xenograft slides with T86 tumors, CD56 was used as
a tumor marker since it was Vimentin negative. The Alexa Flour-488 donkey anti-rabbit (1+100)
was used to detect Vimentin (1+400, EP20, Epitomics) and CSA II Biotin-free Tyramide signal
Amplification System kit (DAKO) was used for detection of CD56 (1+3200, CO4-NCAM, Neo-
markers) in the T86 tissue samples. The nuclei were counterstained with 4´.6 diamidino-2-phemy-
lindole (Dapi) (VWR Internation ApS).
Automated Quantitative analysis
Super images of whole slides were taken at 1.25x magnification using a Leica DM6000 B micro-
scope with an Olympus DP72 camera with bright field settings. Subsequently the region of
interest (ROI), both the core and periphery, was manually outlined for each tumor section
using the Visiopharm Integrator System (VIS) version: 4.5.6.440 (Visiopharm, Hørsholm,
Denmark). Sampling was performed at 20x magnification with a minimum of 15 images in
each ROI. Images were reviewed to ensure that no artifacts or blurring were present. Then
images were analyzed using an algorithm developed in the Visiomorph software module. A
specific classifier was developed for each double-fluorescence staining according to the Visio-
pharmManual. Classifiers were designed and trained so nuclear area corresponding to DAPI
staining of positive cells were measured. In each specific classifier we calculated the total area
of the nuclei of tumor cells of interest (labeled by tumor cell specific marker and marker of
interest) and the total area of remaining tumor cell nuclei (labeled by tumor cell specific marker
but not by marker of interest). From these areas, the nuclear area fraction of tumor cells labeled
by marker of interest was calculated in core and periphery. This fraction was determined based
on the whole mIDH1 positive cell population in each ROI. It was not determined on a single
cell basis, since core areas with very high cellularity did not allow complete separation of the
DAPI stained nuclei.
Fig 1. Double immunofluorescence staining of core and periphery of patient glioblastomas. Histological sections were
stained with Dapi (blue), IDH1 (green) and CD133 (red) (AA-BE), Nestin (red) (CA-DE) and Musashi-1 (red) (EA to FE). The
software-based classifier is shown in the right column. The classifier illustrates tumor cells co-expressing markers of interest in
yellow and tumor cells not co-expressing markers of interest in green. The fluorescence stainings were quantified in both core
and periphery for CD133 (G,J), Nestin (H,K) and Musashi-1 (I,L). Statistical comparison was performed using student’s t-test
and ANOVA, ** p< 0.01. Scalebar: 200μm.
doi:10.1371/journal.pone.0155106.g001
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Statistics
Data was analyzed in GraphPad Prism version 5.01. The comparison of area fraction in the
core and periphery was performed with an unpaired t-test. Statistical significance was defined
as p< 0.05.
Ethics
The official Danish ethical review board named the Regional Scientific Ethical Committee of
the Region of Southern Demark approved the use of human glioma tissue (permission J. No. S-
2011 0022) in the current study. Written informant consent was obtained from all participants.
The use of animals in the present study was approved by The Animal Experiment Inspectorate
in Denmark (J. Nr. 2013/15-2934-00973).
Results
CD133 expression was significantly reduced in migrating tumor cells in the tumor periphery com-
pared to tumor cells in the core region when comparing levels in all tumor samples. Similar but
not significant results were obtained in the different grades and glioma subtypes (Fig 1G and 1J).
Nestin expression was significantly reduced in the periphery for tumor grade II and IV and
for all gliomas together (Fig 1H). For the different glioma subtypes only Oligo-Astrocytoma
(OA) and GBM revealed significantly reduced expression in the periphery although the same
trend was found in the other subtypes (Fig 1K).
The expression of Musashi-1 was significantly reduced in the periphery for grade II and IV and
in all gliomas together (Fig 1I). For the different subtypes of gliomas only GBM had a reduced
expression in the periphery, although the same trend was found in the other subtypes (Fig 1L).
The expression of Sox-2 was reduced in the periphery for all tumor grades and subtypes (S1
Fig) except for the Anaplastic Oligodendroglioma (AO), but without reaching significance (Fig
2G and 2J).
The expression of Bmi-1 was significantly reduced in the periphery of grade II tumors and
all gliomas together (Fig 2H). For subtypes, only the Diffuse Astrocytoma (DA) had a signifi-
cantly reduced expression in the periphery. The expression of Bmi-1 was reduced in the
periphery of all subtypes except the Anaplastic Oligodendroglioma (AO), but without reaching
significance (Fig 2K).
Glut-3 expression was apparently expressed at similar levels in core and periphery (Fig 2I
and 2L).
The expression of Ki-67 was significantly reduced in the periphery for all gliomas together
(Fig 3E). Similar but no significantly reduced expression of Ki-67 in periphery compared to
core was obtained in the different grades and glioma subtypes (Fig 3E and 3G).
MGMT was expressed at similar levels in core and periphery (Fig 3F and 3H).
Comparing expression of the different markers between grades, we did observe a significant
increase in the Ki-67 expression in the core area from grade II to grade IV (Fig 3E). There was
no significant increase of expression of other markers with grade.
Fig 2. Double immunofluorescence staining of core and periphery of patient glioblastomas. Histological sections were
stained with Dapi (blue), IDH1 (green) and Sox-2 (red) (AA-BE), Bmi-1 (red) (CA-DE) and Glut-3 (red) (EA to FE). The software-
based classifier is shown in the right column. The classifier illustrates tumor cells co-expressing markers of interest in yellow and
tumor cells not co-expressing markers of interest in green. The fluorescence stainings were quantified in both core and periphery
for Sox-2 (G,J), Bmi-1 (H,K) and Glut-3 (I,L). Statistical comparison was performed using student’s t-test and ANOVA, ** p< 0.01.
Scalebar: 200μm.
doi:10.1371/journal.pone.0155106.g002
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Fig 3. Double immunofluorescence staining of core and periphery of patient gliomas. Two glioblastomas (AA-BE and CA-DE) were stained with Dapi
(blue), IDH1 (green) and Ki-67 (red) and MGMT (red). The software-based classifier is shown in the right column. The classifier illustrates tumor cells co-
expressing markers of interest in yellow and tumor cells not co-expressing markers of interest in green. The fluorescence stainings were quantified in both
core and periphery for Ki-67 (E,G) and MGMT (F,H). Statistical comparison was performed using student’s t-test and ANOVA, ** p< 0.01. Scalebar: 200μm.
doi:10.1371/journal.pone.0155106.g003
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In the GBM xenografts the different markers were expressed at similar levels in core and
periphery (Figs 4, 5 and 6).
Discussion
Our results suggest that tumor cells in the periphery express CSC-markers both in patient glio-
mas and in orthotopic xenografts. The CSC hypothesis states that tumor growth is driven by a
subpopulation of tumorigenic CSCs [39]. Huang et al. and Bao et al. showed that CSCs in
GBMs were extremely resistant to conventional radiation and chemotherapies [3, 40]. Together
these results suggest that the CSC hypothesis also extend to tumor cells left in the periphery
after surgery, although the vast majority of studies have been performed on removed central
tumor material. The presence of CSCs in the periphery in all glioma grades and sub-types indi-
cates that these CSCs could be the reason for treatment failure and recurrence in glioma
patients. Extending the CSC hypothesis to tumor cells left in the periphery after surgery for all
gliomas is fully in line with the well know observation that macro radical resection of the
tumors increases survival compared to biopsies and suboptimal resection [41, 42].
Expression of CD133 was found at lower level compared to the other stem cell markers.
This observation corresponds to what has been shown in other studies [43]. We have previ-
ously shown that it is of great importance which CD133 clone is used; e.g. whether the CD133
clone targets the non-glycosylated epitope (i.e. the C24B9 clone) or the glycosylated extracellu-
lar epitope (i.e. the AC133 or W6B3C1)[44]. In this study we used the W6B3C1 clone, which
we previously have identified as an antibody clone labeling both membrane and cytoplasm of
tumor cells [44–46]. Most importantly this clone has been shown to be associated with asym-
metric tumor cell division, which is a hallmark of cancer stem cells [44, 47].
For Ki-67, the expression was slightly reduced in the periphery for all gliomas together.
Comparing the expression between grades, we did however observe a significant increase in the
Ki-67 expression in the core area from grade II to grade IV (Fig 3E). There was no significant
increase in expression of other markers together with tumor grade. This is in line with the
results from Sabit et al. [36] who used a similar mIDH1 double fluorescence approach (11
patients). However Sabit et al. did not use a computer-based algorithm, but two independent
neuropathologists to evaluate the tumor samples. The slightly reduced proliferation in the
periphery suggest that both temozolomide and radiation therapy is less efficient in these areas
compared to central tumor areas. This may explain why Ki-67 labeling indices found and used
in prognostic studies, where tumor bulk is removed, not have shown to have a prognostic value
predicted [48, 49]. In most patients, it is in fact the tumor periphery left in the patients, which
receives temozolomide and radiation therapy.
The Ki-67 labeling index correlated with survival should ideally be the index obtained from
the periphery.
For MGMT a similar distribution in the core and periphery was found for all tumor grades
and subtypes. This means that resistance to temozolomide was preserved in migrating tumor
cells. Strategies aiming at reducing chemoresistance by compromising the MGMT enzyme are
therefore highly relevant for migrating glioma cells and new drugs added to temozolomide
should also reach these tumor cells to be efficient.
Fig 4. Double immunofluorescence staining of core and periphery in orthotopic model with five different patient-derived GBM spheroid
cultures. Tissues were stained with Dapi (blue), Vimentin/CD56 (green) and CD133 (red), Nestin (red) and Musashi-1 (red). The software-based
classifier is shown in the right column. The classifier illustrates tumor cells co-expressing markers of interest in yellow and tumor cells not co-
expressing markers of interest in green. The fluorescence stainings were quantified in both core and periphery for CD133 (G), Nestin (H) and Musashi-
1 (I). Statistical comparison was performed using student’s t-test. Scalebar: 200μm.
doi:10.1371/journal.pone.0155106.g004
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In the GBM xenograft mouse model the results showed a similar expression of stem cell
markers in core and periphery for all stem cell markers. Before implantation in mice brains,
the spheroid cultures were grown in neural stem cell medium, which favor a more stem cell
like phenotype. This might explain the preservation of the stem cell phenotype in migrating
xenograft tumor cells compared to the reduced expression of stem cell markers found in
migrating glioma cells in patients. However, to a large extend the overall levels in tumor core in
patients and mice were similar, except for musashi-1 and sox-2 which were expressed at much
higher or higher levels in both core and periphery in patients GBMs compared to GBM xeno-
grafts. Reasons for this may be differences e.g. in tumor microenvironment. Hypoxia is pro-
nounced in patient high grade gliomas and known to increase expression of stem cell markers
[50–52], but necrosis is not found in our GBM xenografts suggesting that this micro-environ-
mental stimulus is less pronounced patients. Another explanation of differences between
results obtained in patient tumors versus GBM xenografts is IDH1 status. The patient tumors
included in this study were all IDH1 mutated whereas all GBM xenografts were obtained from
IDH1 wild type GBMs. Accordingly, CD133 has been found to be expressed at higher levels in
IDH1 wild type GBMs compared to IDH1 mutated GBMs [53]. However, another marker of
Fig 5. Double immunofluorescence staining of core and periphery in orthotopic model with five different patient derived GBM spheroid
cultures. Tissues were stained with Dapi (blue), Vimentin (green) and Sox-2 (red), Bmi-1 (red) and Glut-3 (red). The software-based classifier is
shown in the right column. The classifier illustrates tumor cells co-expressing markers of interest in yellow and tumor cells not co-expressing markers
of interest in green. The fluorescence stainings were quantified in both central part and periphery for Sox-2 (G), Bmi-1 (H) and Glut-3 (I). Statistical
comparison was performed using student’s t-test. Scalebar: 200μm.
doi:10.1371/journal.pone.0155106.g005
Fig 6. Double immunofluorescence staining of core and periphery in orthotopic model with five different patient derived GBM spheroid cultures.
Tissues were stained with Dapi (blue), Vimentin (green) and Ki-67 (red). The software-based classifier is shown in the right column. The classifier illustrates
tumor cells co-expressing markers of interest in yellow and tumor cells not co-expressing markers of interest in green. The fluorescence stainings were
quantified in both core and periphery for Ki-67 (C). Statistical comparison was performed using student’s t-test. Scalebar: 200μm.
doi:10.1371/journal.pone.0155106.g006
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tumor aggressiveness–Ki-67 appeared to be expressed at similar levels in patient GBMs and
GBM xenografts. The expression of Ki-67 in the GBM xenograft model showed a slightly
reduced but not significant reduction in the periphery (n = 5), whereas the slightly reduced
level was significant in patient GBMs (n = 26). In general, our results indicate that the orthoto-
pic model to some degree mimics the migration scenario seen in patients Studies focusing on
characteristics of migrating glioma cells and how they should be targeted could therefore to
some extend be done in the orthotopic model.
In conclusion tumor cells in the periphery of patient gliomas have a stem cell phenotype,
although it is less pronounced than in the tumor core. Novel therapies aiming at preventing
recurrence should therefore take tumor stemness into account. In addition, known resistance
factors like MGMT also seem to be preserved in the periphery of patient gliomas. Migrating
cells in orthotopic glioblastoma xenografts preserve expression and stem cell markers. The
orthotopic model therefore has a promising translational potential.
Supporting Information
S1 Fig. Double immunofluorescence staining of core and periphery of patient gliomas. Dif-
fuse astrocytoma (AA-BE), oligo-astrocytoma (CA-DE), oligodendroglioma (EA-FE), anaplas-
tic astrocytoma (GA-HE) and anaplastic oligo-astrocytoma (IA-JE) were stained with Dapi
(blue), IDH1 (green) and Sox-2 (red). The software-based classifier is shown in the right col-
umn. The classifier illustrates tumor cells co-expressing Sox-2 in yellow and tumor cells not
co-expressing Sox-2 in green. Scalebar: 200μm.
(TIF)
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